JP2022538210A - 腎機能障害患者における高アンモニア血症の治療 - Google Patents

腎機能障害患者における高アンモニア血症の治療 Download PDF

Info

Publication number
JP2022538210A
JP2022538210A JP2021568727A JP2021568727A JP2022538210A JP 2022538210 A JP2022538210 A JP 2022538210A JP 2021568727 A JP2021568727 A JP 2021568727A JP 2021568727 A JP2021568727 A JP 2021568727A JP 2022538210 A JP2022538210 A JP 2022538210A
Authority
JP
Japan
Prior art keywords
hyperammonemia
acid
cargluminic
daily dose
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538210A5 (https=
Inventor
バルキエッリ マルコ
ゴメニ ロベルト
Original Assignee
レコルダティ インダストリア キミカ エ ファーマセウティカ ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レコルダティ インダストリア キミカ エ ファーマセウティカ ソシエタ ペル アチオニ filed Critical レコルダティ インダストリア キミカ エ ファーマセウティカ ソシエタ ペル アチオニ
Publication of JP2022538210A publication Critical patent/JP2022538210A/ja
Publication of JP2022538210A5 publication Critical patent/JP2022538210A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021568727A 2019-05-22 2020-05-21 腎機能障害患者における高アンモニア血症の治療 Pending JP2022538210A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962851339P 2019-05-22 2019-05-22
US62/851,339 2019-05-22
US16/851,999 2020-04-17
US16/851,999 US20200368192A1 (en) 2019-05-22 2020-04-17 Treatment of hyperammonemia in patients with renal insufficiency
PCT/EP2020/064232 WO2020234431A1 (en) 2019-05-22 2020-05-21 Treatment of hyperammonemia in patients with renal insufficiency

Publications (2)

Publication Number Publication Date
JP2022538210A true JP2022538210A (ja) 2022-09-01
JP2022538210A5 JP2022538210A5 (https=) 2023-05-29

Family

ID=73457942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568727A Pending JP2022538210A (ja) 2019-05-22 2020-05-21 腎機能障害患者における高アンモニア血症の治療

Country Status (4)

Country Link
US (3) US20200368192A1 (https=)
EP (1) EP3972580A1 (https=)
JP (1) JP2022538210A (https=)
WO (1) WO2020234431A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628143B1 (en) * 2022-06-14 2023-04-18 Novitium Pharma LLC Tablet for oral suspension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275260A1 (en) * 2013-03-15 2014-09-18 Sanjay Rangnathrao Kawale Preparation Of Stable Pharmaceutical Dosage Forms
WO2018095848A1 (en) * 2016-11-22 2018-05-31 Recordati Industria Chimica E Farmaceutica S.P.A. Pharmaceutical parenteral formulation containing carglumic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275260A1 (en) * 2013-03-15 2014-09-18 Sanjay Rangnathrao Kawale Preparation Of Stable Pharmaceutical Dosage Forms
WO2018095848A1 (en) * 2016-11-22 2018-05-31 Recordati Industria Chimica E Farmaceutica S.P.A. Pharmaceutical parenteral formulation containing carglumic acid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ORGAN BIOLOGY, vol. 25(1), JPN6024015806, 2018, pages 71 - 73, ISSN: 0005562623 *
カーバグル分散錠２００ＭＧ 審査報告書 医薬品製造販売承認申請書 添付資料(株式会社ポーラファルマ), vol. 第２部 ２．５ 臨床に関する概括評価, JPN6024015808, 28 September 2016 (2016-09-28), pages 1 - 70, ISSN: 0005562621 *
日腎会誌, vol. 50（8）, JPN6024015807, 2008, pages 955 - 958, ISSN: 0005562622 *

Also Published As

Publication number Publication date
EP3972580A1 (en) 2022-03-30
US20220040129A1 (en) 2022-02-10
US20200368192A1 (en) 2020-11-26
WO2020234431A8 (en) 2021-03-04
US20220071938A1 (en) 2022-03-10
WO2020234431A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
EP4029498B1 (en) Bis-choline tetrathiomolybdate for treating wilson disease
CN103974619B (zh) 治疗法布里病的给药方案
JP2020045346A (ja) ポンペ病の処置のための投与計画
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
JP2022549621A (ja) アルコール性肝炎の処置
Drewe et al. In Vitro-ln Vivo Correlation for Modified-Release Formulations
JP2022538210A (ja) 腎機能障害患者における高アンモニア血症の治療
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
CA3084100C (en) Bis-choline tetrathiomolybdate for treating wilson disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250401